Retatrutide Enters the Full Record
Full Phase 3 results clarify both the promise—and the limitations—behind an earlier headline.
Two tablets, two questions
Evidence is not approval
No material peptide-focused FDA approval or labeling change was identified during this review window. Retatrutide and EloraTZP remain investigational. Trial results and intended submissions do not establish approval. FDA specifically states that retatrutide is not a component of an approved drug and cannot be used in compounding under federal law. FDA record, reviewed October 1.
Retatrutide: peer-reviewed Phase 3 evidence
TRIUMPH-2 randomized 1,152 adults with type 2 diabetes and obesity or overweight to retatrutide or placebo for 80 weeks. The Lancet publication reported average weight reductions of 11.9%, 16.8% and 18.8% across the three retatrutide groups, versus 5.1% with placebo, using the treatment-regimen estimand. This analysis includes outcomes regardless of treatment discontinuation or specified other events. Peer-reviewed report, September 29.
Lilly highlighted up to 20.8% versus 4.0% with placebo under an efficacy estimand, assuming continued treatment without prohibited weight-management treatments. Both estimates can be accurate; they answer different questions. Gastrointestinal events were common. Adverse-event discontinuation was 3.8%, 11.6% and 7.7% across retatrutide groups, versus 4.9% with placebo. Lilly plans a U.S. submission in the first quarter of 2027; this is not an approval. Lilly disclosure, September 29.
EloraTZP: sponsor-reported Phase 2b evidence
Lilly reported a 48-week, double-blind trial involving 367 adults with obesity or overweight and type 2 diabetes. EloraTZP combines investigational eloralintide with tirzepatide. The highest combination produced 23.3% average weight loss under the efficacy estimand, versus 14.8% with tirzepatide alone. The primary comparison was against placebo; the tirzepatide comparisons were secondary.
Adverse-event discontinuation ranged from 10.8% to 27.0% across combination groups, versus 2.9% with tirzepatide. Phase 3 studies are planned. No peer-reviewed publication of this readout was identified. Lilly disclosure, September 30.
What these reports establish
- Approved use: No new approval for these candidates.
- Controlled human evidence: Peer-reviewed Phase 3 for retatrutide; sponsor-reported Phase 2b for EloraTZP.
- Observational evidence: No material new item met the threshold.
- Animal research: No material new item met the threshold.
- In-vitro mechanisms: No new mechanistic result changes the human evidence.
- Unsupported claims: These trials do not establish guaranteed weight loss or support unsupervised use, compounded copies or individualized dosing claims.
The delivery technology behind the deal
Confirmed disclosure: Nanexa licensed its PharmaShell controlled-release technology to Novo Nordisk for certain therapeutic peptides, with up to five development programs and monthly or quarterly delivery targets. Potential payments total up to €1.165 billion, including upfront and conditional milestones, plus low-single-digit royalties. This is not money already received. No named candidate, human result or commercial manufacturer was disclosed. Nanexa, September 24. The announcement preceded this edition’s window; the market response followed September 25.
Dated market movement: Reuters reported Nanexa shares approximately 122% higher at 07:23 GMT on September 25 following the announcement. This is a dated intraday observation, not a current quote. Reuters, September 25.
Editorial inference: The deal shows commercial interest in less-frequent delivery. It does not demonstrate an approved medicine or guarantee payment of every milestone.
Descriptive market reporting only—not an investment recommendation.
No classification change
The permanent Retatrutide record now distinguishes the treatment-regimen and efficacy estimates. It remains investigational. No Original Disciple profile, artwork or storyline changes.
Further evidence required
Retatrutide has controlled Phase 3 evidence; regulatory review remains ahead. EloraTZP requires Phase 3 confirmation, fuller safety characterization and independent publication. Its discontinuation rates belong beside its efficacy results.
The Estimand Test: How 18.8% and 20.8% Can Both Be Correct
- What TRIUMPH-2 tested
- Treatment-regimen versus efficacy estimands
- Discontinuation and missing data
- Weight and glycemic outcomes in type 2 diabetes
- Gastrointestinal events and dysesthesia
- Evidence required for regulatory review
- Why headline percentages should never stand alone
Sources and conflicts
Primary sources and dates are linked beside each finding. Lilly funded TRIUMPH-2 and owns retatrutide, eloralintide and tirzepatide. Its releases are financially interested sources. Retatrutide’s report is peer reviewed; the EloraTZP readout remains sponsor-reported. Nanexa and Novo have financial interests in the delivery agreement; future milestones, royalties, performance and approvals remain uncertain.
Editorial review: Church of Peptides · Independent clinical review: none to date · Last reviewed October 1, 2026.